Stock Evaluator: Lakewood-Amedex Biotherapeutics, Inc. (LABT)
Lakewood-Amedex Biotherapeutics, Inc. LABT
$1.94
-0.13
-6.28%
September 3, 2026 10:45:48 AM
EST
Volume: 101,502
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs. It also develops Nu-3, a topical antimicrobial for infected diabetic foot ulcers, which is in Phase 2b clinical trial. The company was formerly known as Lakewood-Amedex Inc. and changed its name to Lakewood-Amedex Biotherapeutics, Inc. in June 2025. Lakewood-Amedex Biotherapeutics, Inc. was incorporated in 2006 and is headquartered in University Park, Florida.
Financial Summary
| Share Statistics | LABT | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $4.9 | $288.9 | 3% |
|
| Shares Out (Mil) | 1.4 | 54.0 | 6% |
|
| Institutional Ownership | 10.8% | 93.1% | 7% |
|
| Float (Mil) | 1.0 | 41.4 | 3% |
|
| Beta | na | 0.94 | na |
|
| Avg Daily Volume (000s) | 1,884 | 480 | 82% |
|
| Price Change (52-week) |
na | 59.9% | na |
|
| Growth | LABT | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.1% | na |
|
| Net Income (5yr) | na | (10.1%) | na |
|
| EPS (5yr) | na | 15.9% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | LABT | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($7) | ($43) | 31% |
|
| EPS (TTM) | ($10.200) | ($1.500) | 4% |
|
| Operating Cash Flow (TTM) (Mil) | ($4) | ($31) | 27% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $1 | $190 | 4% |
|
| Valuation | LABT | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.03 | 2.84 | 23% |
|
| P/E | na | 20.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | LABT | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.9% | na |
|
| Net Margin | na | (74.2%) | na |
|
| ROA | (225.4%) | (47.7%) | 2% |
|
| ROE | (403.2%) | (55.0%) | 2% |
|
| Liabilities to Assets | 12.7% | 29.6% | 8% |
|
| F-Score | 2 | 3 | 7% |
|
Lakewood-Amedex Biotherapeutics, Inc. did not pass any screens on 9/2/2026.
